Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9113781 | 0.95 | ALPI (0.59) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL14359605 | 0.93 | CHRNB2 (0.63) | MMP2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL12085491 | 0.93 | CHRNB2 (0.63) | MMP2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL11254327 | 0.92 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL18375234 | 0.92 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL17337848 | 0.91 | ALPI (0.54) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL16559587 | 0.90 | ALPI (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL2927527 | 0.90 | ALPI (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL21010316 | 0.89 | SLC15A1 (0.64) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL13496530 | 0.88 | ALPI (0.51) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170144969-A1 | ANTIMICROBIAL CONJUGATES, METHOD FOR PRODUCTION AND USES THEREOF | THE SECRETARY OF STATE FOR HEALTH (GB) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170144969-A1 | ANTIMICROBIAL CONJUGATES, METHOD FOR PRODUCTION AND USES THEREOF | SRM, SMS, SMOX | MMP2 1172/4885ALPI 1656/4885PKM 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.